Imatinib Completed Phase 2 Trials for Head and Neck Carcinoma / Squamous Cell Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00485485Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
NCT00045669Imatinib Mesylate in Treating Patients With Salivary Gland Cancer